Expert Interview
Understanding the latest R&D advances and clinical development trends in obesity management
Ticker(s): RHHBY, AMGN, AZNInstitution: Harvard Medical School
- Medical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor, Harvard Medical School.
- Manages ~1,000 patients with diabetes.
- Co-Investigator of two landmark studies: the national Diabetes Prevention Program and the Look AHEAD (Action for Health in Diabetes) Study.
- Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss.
What are the driving reasons behind the latest increased interest in GLP1+GPR dual agonists?
Added By: pharmaadvisorWhat is the KOL's perception of Roche’s acquisition of Carmot Therapeutics and their pipeline for GLP-1/GIP Receptor Agonists? What is the potential of Carmot's pipeline to accelerate and extend weight loss? All three of Carmot’s assets have combination potential with Roche’s current products. How will this impact the perception of KOLs on potential future treatment, especially with CT-388?
Added By: pharmaadvisorWhat is the KOL's opinion of Amgen's obesity management development pipeline programs, including their maridebart cafraglutide (AMG-133) asset, the once monthly GIPR antagonist, and GLP-1R agonist?
Added By: pharmaadvisorWhat are the trends and reasons companies are increasing investment into combination therapy for obesity?
Added By: pharmaadvisorWhat do KOLs think about oral GLP-1 in terms of its value, positioning, and potential, given the current development work being done in obesity?
Added By: pharmaadvisorWhat’s the next big thing in obesity after the current efficacy/GLP-1 focus? Are there any novel targets of interest?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
